North America Anti-Infective Agents Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2026)

USD 34.12 Billion

Market (2034)

USD 46.80 Billion

CAGR

4.03%

Major Markets Players

Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., GSK plc, Novartis AG and Others

*Note: Partial List Randomly Ordered

North America Anti-Infective Agents Market Key Takeaways

North America Anti-Infective Agents Market Insights & Analysis

The North America Anti-Infective Agents Market is anticipated to register a 4.03% CAGR during 2026–2034. The market size was valued at USD 34.12 billion in 2026 and is projected to reach USD 46.80 billion by 2034. Sustained market momentum is supported by a high prevalence of bacterial, viral, and fungal infections across the United States, Canada, and Mexico, combined with robust government-backed antimicrobial stewardship initiatives. The U.S. Centers for Disease Control and Prevention continues to allocate substantial funding toward surveillance of drug-resistant pathogens, reinforcing demand for next-generation anti-infective therapies across hospital and outpatient settings.

Pharmaceutical companies across the region continue investing in novel antibiotic development pipelines and antifungal agents as resistance profiles of common pathogens grow increasingly complex. Gilead Sciences reported antiviral revenue exceeding USD 27 billion globally in 2024, reflecting the scale of infectious disease treatment demand. Federal initiatives including the CARB-X program have collectively granted over USD 500 million to support early-stage antibacterial research, reinforcing the innovation pipeline. These sustained investments, combined with expanding access to prescription anti-infectives through retail pharmacy networks, are expected to drive consistent market growth through the forecast period.

North America Anti-Infective Agents Market Dynamics

The North America Anti-Infective Agents Market continues gaining momentum as healthcare systems intensify efforts against bacterial, viral, fungal, and parasitic infections amid growing antimicrobial resistance pressures. Expanding hospital formularies, increasing outpatient prescription volumes, rising government stewardship initiatives, and sustained pharmaceutical R&D investment collectively reinforce demand for effective anti-infective therapies across diverse clinical settings throughout the forecast period.

North America Anti-Infective Agents Market Segment-wise Analysis

The North America Anti-Infective Agents Market is segmented by route of administration and distribution channel, with each segment reflecting distinct clinical workflows, patient population characteristics, and institutional procurement patterns that collectively shape revenue contribution across the forecast period.

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

Oral anti-infective agents dominate the route of administration segment, accounting for an estimated 52% market share driven by their widespread applicability across outpatient bacterial infections, antiviral treatment regimens, and long-term prophylactic protocols. The convenience of oral dosing, combined with strong patient adherence rates and extensive availability through retail pharmacies, makes this route the preferred choice for community-acquired pneumonia, urinary tract infections, and influenza antiviral treatment across the United States and Canada. Established oral agents such as amoxicillin-clavulanate, azithromycin, and oseltamivir continue generating consistent prescription volumes across both primary care and specialty settings.

Parenteral anti-infective agents represent the second-largest sub-segment, commanding approximately 33% share as they serve critical care, surgical prophylaxis, and hospital-acquired infection treatment where oral bioavailability is insufficient. Topical agents address dermatological, ophthalmic, and wound care infections with growing adoption driven by the expanding market for topical antifungal and antibacterial formulations in outpatient dermatology clinics. The Others category includes inhalation-route anti-infectives such as tobramycin inhalation solution for cystic fibrosis-associated Pseudomonas infections, representing a specialized but clinically significant segment with robust pricing power.

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Hospital pharmacies dominate the distribution channel segment with an estimated 48% market share, reflecting the concentration of parenteral anti-infective dispensing, formulary management, and inpatient infectious disease pharmacotherapy within institutional pharmacy departments. Academic medical centers and large health systems maintain dedicated infectious disease pharmacist roles to optimize anti-infective selection, monitor for adverse drug interactions, and implement stewardship protocols that influence procurement decisions for high-cost agents including daptomycin, ceftazidime-avibactam, and isavuconazole. Government-negotiated contract pricing and group purchasing organization agreements further reinforce hospital pharmacy's dominant channel position.

Retail pharmacies are expanding their anti-infective dispensing role as outpatient prescription volumes grow, capturing approximately 38% share through chain pharmacy networks and independent community pharmacies. Gilead's HIV antiviral portfolio, including bictegravir-containing regimens, is substantially dispensed through specialty retail pharmacy channels, illustrating the shift of complex anti-infective management into ambulatory settings. The Others segment encompasses mail-order pharmacies, specialty pharmacy distributors, and direct institutional procurement pathways that serve long-term care facilities and correctional healthcare systems, segments that are gaining relevance as ambulatory infection management continues expanding beyond traditional hospital settings.

Country Projection of North America Anti-Infective Agents Market

The North America Anti-Infective Agents Market demonstrates meaningful variation across constituent countries based on healthcare infrastructure maturity, prescription regulatory frameworks, publicly funded antimicrobial stewardship investment, and the relative burden of infectious diseases at the population level.

• United States: The United States commands approximately 78.4% of the regional market, anchored by the highest per-capita pharmaceutical expenditure in North America, advanced hospital formulary systems, and the world's most active anti-infective clinical trial landscape. Pfizer and Merck continue generating substantial revenue from antibiotic and antiviral portfolios, while emerging biotech companies funded through BARDA and NIH grants are advancing novel beta-lactamase inhibitors, phage therapies, and broad-spectrum antifungals that will progressively enter commercial formularies through 2034.
• Canada: Canada represents the fastest-growing national market within the region, supported by Health Canada's progressive antimicrobial stewardship framework and expanding provincial drug coverage for high-cost anti-infective agents. Federal investments exceeding CAD 100 million toward the Pan-Canadian Action Plan on Antimicrobial Resistance are reinforcing both surveillance infrastructure and clinical guideline development that promote formulary-appropriate prescribing.
• Mexico: Mexico is expanding its anti-infective market through investments in hospital infrastructure, increasing access to branded generics, and a rising burden of respiratory and enteric infections. Novartis and GSK maintain active commercial operations across the Mexican pharmaceutical market, with hospital pharmacies in major urban centers increasingly stocking advanced anti-infective agents aligned with international treatment guidelines.
• Rest of North America: Caribbean and Central American nations within this grouping represent smaller but developing markets where international health organizations continue supporting access to essential anti-infectives, particularly for tuberculosis, HIV, and neglected tropical disease treatment programs, gradually expanding the commercial addressable base.

North America Anti-Infective Agents Market: Recent Development (2025)

• Pfizer Inc. expanded its hospital anti-infective portfolio by launching a new carbapenem-sparing combination therapy option.
• Gilead Sciences received FDA approval for an extended-release HIV antiviral regimen improving outpatient treatment adherence significantly.
• Merck & Co. strengthened its antifungal pipeline through a strategic partnership with a leading North American biotech firm.
• GSK plc announced a multi-year antimicrobial stewardship collaboration with U.S. academic medical centers supporting resistance surveillance.

North America Anti-Infective Agents Market Future Outlook (2034)

The North America Anti-Infective Agents Market is projected to expand at a 4.03% CAGR, reaching approximately USD 46.80 billion by 2034. Sustained growth will be driven by the commercial maturation of next-generation antiviral and antifungal agents, expanding antimicrobial resistance-driven formulary shifts toward reserve antibiotics, and increasing government-backed procurement programs that support equitable access to anti-infective therapies across underserved populations. Pharmaceutical companies are expected to continue prioritizing infectious disease pipelines as regulatory pathways such as LPAD and QIDP designations improve development economics for novel compounds.

Long-term market expansion will also be supported by advances in precision infectious disease diagnostics, with rapid molecular diagnostic platforms for anti-infective stewardship enabling more targeted prescribing that elevates demand for narrow-spectrum agents with strong efficacy evidence. The growing burden of fungal infections in immunocompromised populations - including transplant recipients and patients on biologics - will further expand the antifungal segment, while ongoing HIV therapy innovation from Gilead, ViiV Healthcare, and emerging biosimilar developers will sustain antiviral revenue momentum across both institutional and retail pharmacy channels through the end of the forecast period.

North America Anti-Infective Agents Market Report Coverage

Why Choose This Report?

• Comprehensive analysis covering anti-infective drug classes across North American markets.
• Accurate market sizing with reliable 4.03% CAGR forecast through 2034.
• Detailed segmentation covering route of administration and distribution channel dynamics.
• Country-level insights for the United States, Canada, Mexico, and Rest of North America.
• Competitive profiling of leading pharmaceutical players and emerging pipeline companies.
• Analysis of antimicrobial resistance trends driving formulary and procurement shifts.
• Strategic insights supporting investment, licensing, and market entry decisions.
• Data-driven research aligned with FDA regulatory frameworks and stewardship guidelines.